Take advantage of Eurofins Discovery’s SafetyScreen™ in vitro profiling panels, tailored to your needs and based on our standard target based-assays, for rapid and accurate assessment, prediction, and mitigation of potential off-target adverse drug reaction (ADR) risks.
The International Conference on Harmonization (ICH) in their Guidance for Industry (incl. the S7A Safety Pharmacology Studies for Human Pharmaceuticals), states that “ligand binding or enzyme assay data suggesting a potential for adverse effects should be considered in the selection and design of safety pharmacology studies (ICH S7A: 2.2, 3), and specific assessment of the human either-a-go-go-related gene (hERG) channel in the ICH S7B, as well as assessment of the abuse potential of drugs”.
To identify unsafe compounds earlier in your drug discovery programs, and design/select better drug candidates, our standard in vitro pharmacology profiling panels include:
- Tier 1: Binding and functional panels to identify potential ADRs early in the drug discovery process.
- Tier 2: Safety profiling panels are compatible with the optimization phases of drug discovery to build structure-activity relationship (SAR) models and guide chemical design.
- Tier 3: Comprehensive profiling panels providing deeper mechanistic understanding for the selection of key candidates to proceed to early human trials.
| Tier 1 In Vitro Safety Pharmacology Profiling Panels | |
|---|---|
| Panel Name | Key Features |
| Tier 1 core panels include well-established targets and pathways as contributors to clinical ADRs, providing a minimum list of targets for early hazard identification, off-target-related risk assessment, and mitigation. Based on the findings from Reducing safety-related drug attrition: the use of in vitro pharmacological profiling (Nature Rev Drug Discov 11, 909-922, 2012) doi:10.1038/nrd3845 and the IQ DruSafe 2024 publication, The State of the Art in Secondary Pharmacology and Its Impact on the Safety of New Medicines (Nat Rev Drug Discov, 2024, Brennan, R. J. et al.) https://doi.org/10.1038/s41573-024-00942-3., the SafetyScreen panels (SafetyScreen18 Core, SafetyScreen44 Binding, SAFETYscan47 & SafetyScreen Functional) are key for early safety evaluation of drug candidates for clinical adverse event predictions. Testing compounds in both functional and binding assays provides comprehensive assessments, refining predictive safety data to guide decision-making in drug discovery. | |
| Tier 2 In Vitro Safety Pharmacology Profiling Panels | |
|---|---|
| Panel Name | Key Features |
| Tier 2 in vitro Safety Pharmacology Profiling panels provides essential data for lead optimization, supporting SAR model development, guiding chemical design, and addressing potential off-target related liability based on SAR knowledge. The SafetyScreen59 Extended Panel is the perfect follow-up of the SafetyScreen18 Core Panel, offering complete coverage of the most critical targets without redundancy for early safety assessment. The SafetyScreen PLUS delivers comprehensive coverage by combining all targets from SafetyScreen18, SafetyScreen44, SafetyScreen59, and SafetyScreen87 panels. |
|
| Tier 3 In Vitro Safety Pharmacology Profiling Panels | |
|---|---|
| Panel Name | Key Features |
| Tier 3 in vitro Safety Pharmacology Profiling Panels provides a comprehensive mechanistic understanding of off-target liabilities, facilitating the selection of key candidates to progress into first-in-human trials. | |
Visualize Your Result with Our In Vitro Safety Insight Tool
To facilitate results interpretation and identify safety liabilities earlier, our experts developed a visualization tool, the In Vitro Safety Insight. This innovative tool delivers:
- Quick overviews of pharmacological results
- Highlights organs at risk using a custom hazard scoring system.
- Suggests follow-up assays to mitigate potential (AEs)
Customize Your In Vitro Safety Pharmacology Profiling Panels
In addition to Eurofins Discovery’s pre-designed standard panels, we provide the flexibility to design custom panels tailored to fit the specific needs of your drug discovery program. When creating a custom safety pharmacological panel, you will have access to our in vitro assay scientists, which have extensive experience in various therapeutic areas, target types, assay formats, and instrument/automation platforms. We will partner with you to ensure your custom panel is designed accordingly to your specifications, providing the support you need for accurate, reliable results.
Our extensive portfolio of over thousands of in vitro assays can be integrated into a custom panel, covering a wide range of target types (GPCRs, Ion Channels, Kinases, Transporters, Nuclear Receptors, Epigenetic Targets, Growth Factor Receptors, Phosphatases & Proteases, Ubiquitin Enzymes, etc.).
Contact us to learn how our global team of technical experts can help design a custom Safety Profiling Panel to drive your drug discovery program forward.
